Neuroimmunological Model of Traumatic Memory
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00396695|
Recruitment Status : Unknown
Verified November 2006 by Ziv Hospital.
Recruitment status was: Recruiting
First Posted : November 7, 2006
Last Update Posted : November 7, 2006
Traumatic events may lead to strong emotional episodic memories common in Post- Traumatic Stress Disorder(PTSD). Intense affect may inhibit efficacy of glutamatergic neurotransmission in two particular areas of the limbic system that have been implicated in the processing of emotionally charged memories: the amygdala and the hippocampus(1,2).
Dysfunction of glutamatergic neurotransmission is associated with disbalance of long-term potentiation (LTP) and long-term depression (LTD)- two underlying mechanisms that cooperate to achieve synaptic plasticity and its expressations- learning and memory(3). LTP- the long lasting enhancement of synaptic function includes changes in the amount of neurotransmitter glutamate released into a synapse, changes in the levels of key proteins in synapses, protein phosphorylation and changes the density of receptors on their synaptic membranes. LTD is the inverse of LTP, a long lasting reduction in synaptic transmission (4). Interactions among the different forms of plasticity underlie different forms of memories. Normally these mechanisms are balanced.
In the current literature there is data that a class I major histocompatibility complex (MHC class I) molecules, known to be important for immune responses to antigen, are expressed also by neurons that undergo activity-dependence, long-term structural and synaptic modifications (5). The brain produces its own immune molecules, the proteins MHC class I and CD3-zeta (a component of receptors for MHC class I). In the immune system, the two proteins act as part of a lock and key system to recognize and get rid of the body’s foreign invaders. The CD3-zeta polypeptide is component of the T cell antigen receptor (TCR) which contribute to its efficient cell surface expression and account for part of its transducing capability (6).
In the brain, they may be part of a signaling system that recognizes and eliminates inappropriate neural connections. Expression of MHC class I is regulated by the naturally occurring electrical activity, and sensitive to both natural and pathological changes in the activity. Electrical activity of neurons drives to an establishment of the final pattern of connection. Changes in the strength of individual synapses such as potention and depression leads to stabilization and withdrawal, respectively, of the affected connections. There are data, that in mice with deficiency of MHC class I and CD3-zeta the LTP in the hippocampus is enhanced significantly and LTD is absent. Thus, MHC class I is crucial for translating activity into changes in synaptic strength and neuronal connectivity in vivo. He required for normal activity dependent potentiation, depression, removal of inappropriate connection and responding to injury in the CNS (6).
Glutamate receptors play critical roles in LTP/LTD mechanisms. Some researchers consider that a key role in pathogenesis of PTSD is being played by excessive excitation of NMDA-receptors in limbic system structures (1). The existing data allows to assume, that equation of plasticity mechanisms depends on mutual relations between the MHC class I and glutamate receptors.
T-cells, like neurons, express high levels of glutamate receptors that are identical to the brain glutamate receptors. Presence of ionotropic and metabotropic glutamate receptors in membranes of lymphocytes makes them sensitive to the same alarm molecules which operate neuronal activity. Glutamate by itself triggers several T-cell activation which differs quantitatively or qualitatively from that ones triggered by “classical’ T-cell activators like antigens(7). There are data about influence of T cell receptor-CD3 complex- on the expression of T-cells glutamate receptors (8). It is possible, that the key roles in this function play CD3-zeta.
|Condition or disease||Intervention/treatment|
|Stress Disorders, Post-Traumatic||Procedure: Blood test|
Working hypothesis and aims
Trauma-related LTP/LTD disbalance in favor of potentaion and excessive excitation of glutamate receptors generated when arousing experiences occur in conjunction with memory-related activation of the hippocampus and amigdala. Traumatic memories connected to the amplification of mechanism LTP, when new information is unable to induce reliable LTD, which reverses synaptic plasticity formed during previous emotional learning experiences.
MHC class I and CD3-zeta play a key role in these changes. We assume that the composition of glutamate receptors and CD3-zeta expression in T-cells can be used as the model reflecting for LTP/LTD balance in CNS.
The work includes the learning of following parameters:
- The Expression in T-cells: glutamate receptors, CD3-zeta.
- Glutamate level in plasma
Cytokines levels in plasma:
- interferon-γ that can induce some components of class I MHC (9).
- tumor necrosis factor-α that influences the AMPAR expression and plays a role in LTP reduction (10).
Groups (of 20 people each) will make patients with a priori various degree of LTP/LTD balance: healthy people and PTSD patients.
People suffering PTSD, frequently have conditions when they again, brightly and deeply experience event injuring them. The memoirs painted by painful emotions, seize attention of the person and then it seems to him as if he again experiences injuring event and sees it as real.
We assume, that it is connected to the unable to induce reliable LTD, and that the composition of glutamate receptors and CD3-zeta expression in T-cells such people should differ from healthy.
Used method: enzyme- linked immunosorbent assay (ELISA), FACS
|Study Type :||Observational|
|Enrollment :||40 participants|
|Observational Model:||Defined Population|
|Official Title:||Neuroimmunological Model of Traumatic Memory|
|Study Start Date :||October 2006|
|Study Completion Date :||December 2007|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00396695
|Contact: Alexander Mizruchin, MD||+ 972 50 8434245|
|Contact: Igor Krasnov, Ph.D||+ 972 4 email@example.com|
|Sieff Government Hospital||Recruiting|
|Safed, Israel, 13110|
|Contact: Igor Krasnov, Ph.D + 972 4 682 8828|
|Principal Investigator: Alexander Mizruchin, Ph.D|
|Sub-Investigator: Igor Krasnov, Ph.D|
|Principal Investigator:||Alexander Mizruchin, MD||Sieff Government Hospital|